- September 2014
Discussing how healthcare systems can meet the needs of cancer survivors.
- July/August 2014
Sophie Postel-Vinay on new recommendations for phase 1 trials.
- June 2014
Hans Clevers on important research into stem cells in normal gut tissue.
- May 2014
Carolyn Taylor and Paul McGale find evidence to clarify guidelines for radiotherapy after mastectomy.
- April 2014
Richard Sullivan and Ajay Aggarwal on how physicians can tackle the issue of affordability in cancer care.
- March 2014
The 1st EORTC Cancer Survivorship Summit addressed the practical problems faced by cancer patients.
- February 2014
Charles Swanton on a study that maps genetic changes in cancers over time.
- January 2014
Presidents of various cancer societies make predictions for the coming year.
- December 2013
Precision diagnostics have great potential, but changes are needed to make them more available.
- November 2013
Highlights of the European Cancer Congress - cancer society presidents give their view.
- October 2013
Richard Schilsky on the changes needed as personalised medicine enters the clinic.
- September 2013
A new advance in immunotherapy is discussed by Jean-Charles Soria and Caroline Robert.
EJC News Focus – October 2013
'New ways of learning are needed' as personalised medicine enters routine practice
Prospective observational registries, which record every clinical encounter with every patient, are going to be the way to continue progress in our understanding of cancer, according to Richard L Schilsky, Chief Medical Officer of the American Society of Clinical Oncology (ASCO).
Genetic characterisation has led to cancers which were traditionally considered common becoming instead a collection of rare diseases. It means that there are now too many cancers, too many drugs in development and not enough patients, time or money to study everything by doing clinical trials, he says.
In this month's EJC News Focus, Schilsky tells Helen Saul that as personalised medicine enters the clinic, changes are needed – and are happening – in research, development and the regulation of new cancer drugs.